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Introduction: Studies on the transactivation of genes via pro-
moter elements have mostly been done on cell lines rather than
resected tissues. This, however, is essential to address an
in vivo or clinical relevance. We have previously shown tumor-
specific binding of Sp1and an activator protein (AP)-2a related fac-
tor to promoter region -152/-135 of the metastasis-related u-PAR
gene in 60% of in vivo resected cancer tissues. Cell lines have
implicated an additional role, and potential synergism, of an
AP-1 region (-190/-171) in u-PAR regulation. This study was done
to (a) analyze AP-1 binding to this region in resected tumor and
normal tissues, and define subgroups in which it is tumor-spe-
cific, and (b) to analyze transcription factor binding patterns to
both promoter motifs in resected tissues, supporting synergism,
and draw first prognostic conclusions.
Methods: In 103 patients with colorectal cancer, electrophoretic
mobility shift assay/supershift analysis for u-PAR promoter
region -190/-171 was done in tumors and normal tissues. In 71
patients, region -152/-135 was also analyzed. U-PAR protein was
measured by ELISA.
Results: Tumor-specific AP-1 binding to region -190/-171 of the u-
PAR promoter was found in 40% of patients. Subgroup analysis
showed tumor-specific binding for c-Fos in 58%, for c-Jun in
50%, for JunD in 39%, and for Fra-1 in 4% of cases. AP-1 binding
correlated significantly with u-PAR protein amounts in both nor-
mal and tumor tissues (p < 0.001), in contrast to a tumor-specific
correlation with u-PAR of the AP-2/Sp1 region. In analyses for
both promoter regions, 62% of cancers showed simultaneous
binding for AP-1, AP-2, and Sp1, 11% for AP-1 and AP-2, 16% for
AP-2 and Sp1, 4% for AP-2 only, 3% for AP-1 only, and 0% for
Sp1 only. The binding of AP-1, AP-2, and Sp1 correlated signifi-
cantly with each other (p < 0.001), the combination of AP-1 and
AP-2 showing the highest correlation with u-PAR (p = 0.008). Preli-
minary survival analysis indicated a trend for poorer prognosis
for binding of all three transcription factors.
Conclusion: This is the first study differentiating transcription
factor binding to two important u-PAR promoter regions in a large
series of resected tumors and normal tissues. The AP-1 site seems
to be a less tumor-specific regulator than the Sp1/AP-2 motif.
Nevertheless, data corroborate the hypothesis of synergism
between both elements in resected tumors.
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Background: Tumor-suppressor Pdcd4 has never been investi-
gated as to a potential role in invasion/metastasis. The urokinase
receptor (u-PAR) promotes invasion and metastasis and is associ-
ated with a poor cancer-patient survival. The present study was
conducted: (1) to implicate a role of Pdcd4 in invasion and u-
PAR-regulation, (2) to describe first mechanisms by which this is
achieved.
Methods: Diverse gastrointestinal carcinoma cell lines were
screened for Pdcd4- and u-PAR expression and protein amounts
by Northern-, Western blot analysis respectively RT-PCR. To deter-
mine a potential regulation of the u-PAR promoter by Pdcd4, CAT-
and luciferase reporter assays using diverse u-PAR wildtype and
deletions mutants were undertaken and potential cis-element
were screened for transcription factor binding by EMSA. Invasion
and intravasation influenced by Pdcd4 were tested by using differ-
ent invasion assay approaches.
Results: In colon/gastric cancer cell lines, a reciprocal expression
of u-PAR and Pdcd4 was observed. RKO and HCT116 colon cancer
cells made to express Pdcd4 showed a reduction in u-PAR-mRNA
and -protein, this being paralleled by an inhibition of invasion/
intravasation. A CAT-reporter driven by the wildtype u-PAR-pro-
moter was reduced in constitutive activity with increasing
Pdcd4-expression. Deletion of a region containing a putative
Sp-1 binding site at -402/-350 inhibited u-PAR-promoter regula-
tion by Pdcd4, this being paralleled by a reduction of Sp1 binding
to this region in pdcd4-transfected cells. Pdcd4-transfected
cells showed an increase of Sp3 binding to u-PAR-promoter region
-152/-135, and the deletion of this region reduced the ability of
Pdcd4 to suppress u-PAR-promoter activity.
Conclusion: These data suggest Pdcd4 as a new negative regula-
tor of invasion and the invasion-related gene u-PAR. Furthermore,
it is the first study to implicate Pdcd4-induced gene expression
via Sp3 induction and Sp1 suppression.
doi:10.1016/j.ejcsup.2006.04.064
P5. EVIDENCE OF Pdcd 4 AS A NOVEL MARKER FOR
TUMOR DIAGNOSIS AND PROGRESSION IN RESECTED
COLORECTAL CARCINOMAS
F. Medveda,1, R. Grobholzb,1, C. Josta, G. Muddulurua, J.H. Leupolda,
J. Schumachera, N.H. Colburnd, S. Postc, H. Allgayera. aDepartment
of Experimental Surgery Mannheim, University Heidelberg, and
Molecular Oncology of Solid Tumors Unit, DKFZ Heidelberg, Theodor-
Kutzer Ufer 1-3, 68135 Mannheim, Germany; bDepartment of Pathology
